However, detailed analyses of these non-canonical sphingolipids derived from SPTLC3, their downstream incorporation into ceramides, and their potential mechanistic contributions to NAFLD have not been conducted, which could further expand the possibilities for the development of therapeutic approaches. This evidence concerns the gene SPTLC3 and metabolic dysfunction-associated steatotic liver disease.